Gastroenterology

GLP-1 Disruption. Colorectal Cancer. Diagnostic Risk. Device Innovation.

Section analysis by Oksana Pokoyeva, COC, CPC, CPCO, CPC-P, CPMA, CUC, Billing Department, WCH

Editorial note: The articles in this section combine confirmed clinical guidance, published research, and analytical interpretation of emerging trends. GLP-1-related clinical guidance is actively evolving; where guidance has shifted between publication cycles, this is noted in context. Statements about symptom overlap and diagnostic risk reflect plausible clinical concerns raised in the GI literature and specialty discussions — not established causal findings. Readers should consult current ASA, ACG, and ASGE guidance and qualified clinical advisors before modifying practice protocols. This section is for informational and educational purposes and does not constitute medical, legal, or compliance advice. Current evidence does not suggest that GLP-1 receptor agonist therapy increases colorectal cancer incidence.

Gastroenterology in 2026 is navigating the clinical and operational consequences of GLP-1 receptor agonists — a drug class that has moved from metabolic medicine into the daily workflow of every GI practice. The procedural safety considerations, the diagnostic complexity, and the screening implications of widespread GLP-1 use are reshaping how gastroenterologists manage their patients and their practices.

At the same time, the epidemiology of colorectal cancer is shifting in ways that were already concerning before GLP-1 use became widespread. Early-onset CRC continues to rise. The intersection of that trend with GLP-1 symptom overlap has prompted discussion in the GI community about whether symptom attribution patterns may, in some cases, contribute to delayed diagnostic evaluation — a concern that is plausible, actively discussed, and not yet supported by established population-level evidence. On the business side, a new generation of advanced endoscopic devices is expanding ASC procedural capabilities, while sustained top-tier compensation and intensifying PE consolidation pressure are reshaping the competitive landscape for independent GI groups.

In this Section

Article 01 · Clinical Operations
GLP-1 Drugs Have Significantly Affected Endoscopy and Colonoscopy Practice — Every GI Group Needs Updated ProtocolsDelayed gastric emptying and aspiration risk are established considerations for GLP-1 patients undergoing endoscopy. How guidance has evolved from 2023 to 2024 — and what operational protocols practices need in place.

Article 02 · Clinical Risk & Diagnosis
GLP-1 Side Effects Overlap with Colorectal Cancer Warning Signs — a Diagnostic Concern Gastroenterologists Are Increasingly Discussing
Symptom overlap between GLP-1 adverse effects and early CRC presentation has raised concern about diagnostic attribution in some patients. What the current evidence does and does not support.

Article 03 · Epidemiology & Screening
The Younger Colorectal Cancer Surge Continues — and GLP-1 Symptom Overlap Is Adding Diagnostic ComplexityEarly-onset CRC is well-documented and rising. The convergence with GLP-1 symptom profiles adds a layer of diagnostic complexity that the specialty is working to address — without yet having consensus protocols.

Article 04 · Technology & Market Structure
New GI Devices Are Expanding ASC Capabilities — and Reshaping the Business Case for Independent GI PracticeA 2026 wave of advanced endoscopic devices is moving complex GI procedures to outpatient settings. Combined with top-tier compensation and PE consolidation pressure, the strategic calculus for GI practices is shifting.